FDA Approves New Option for Intra-abdominal Infections

The FDA has approved Xerava (eravacycline) for the treatment of complicated intra-abdominal infections (CIAIs) in patients aged 18 years and older.

The approval of the injectable, fully synthetic fluorocycline antibiotic was based upon the results of several clinical trials in which the drug was well tolerated and achieved high cure rates in patients with CIAI and was statistically noninferior to ertapenem and meropenem.

The most common adverse reactions associated with Xerava use were infusion site reactions, nausea, and vomiting.

—Michael Potts

Reference:

Tetraphase Pharmaceuticals Announces FDA Approval of XERAVA™ (Eravacycline) for Complicated Intra-Abdominal Infections (cIAI) [press release]. Tetraphase Pharmaceuticals. Watertown, Massachusettes. August 27, 2018.. https://ir.tphase.com/news-releases/news-release-details/tetraphase-pharmaceuticals-announces-fda-approval-xeravatm.